Profil

Fransolet Gilles

Main Referenced Co-authors
Baron, Frédéric  (30)
Beguin, Yves  (29)
Ehx, Grégory  (29)
Hannon, Muriel  (27)
Delens, Loïc  (22)
Main Referenced Keywords
GVHD (14); Th17 (9); Azacytidine (5); Imatinib (5); Fibrosis (4);
Main Referenced Unit & Research Centers
GIGA-I3 - Giga-Infection, Immunity and Inflammation - ULiège [BE] (13)
Giga-Infection, Immunity and Inflammation Laboratoire d'hématologie (8)
Main Referenced Disciplines
Hematology (17)
Biochemistry, biophysics & molecular biology (10)
Immunology & infectious disease (4)

Publications (total 31)

The most downloaded
784 downloads
SERVAIS, S., BEGUIN, Y., Delens, L., Ehx, G., Fransolet, G., Hannon, M., WILLEMS, E., Humblet-Baron, S., Belle, L., & Baron, F. (11 May 2016). Novel approaches for preventing acute graftversus- host disease after allogeneic hematopoietic stem cell transplantation. Expert Opinion on Investigational Drugs, 9, 957-972. doi:10.1080/13543784.2016.1182498 https://hdl.handle.net/2268/196156

The most cited

51 citations (Scopus®)

Ehx, G., Fransolet, G., De Leval, L., D'Hondt, S., Lucas, S., Hannon, M., Delens, L., DUBOIS, S., Drion, P., Beguin, Y., Humblet-Baron, S., & Baron, F. (2017). Azacytidine prevents experimental xenogeneic graft-versus-host disease without abrogating graft-versus-leukemia effects. Oncoimmunology, 6:e1314425. doi:10.1080/2162402X.2017.1314425 https://hdl.handle.net/2268/210001

Delens, L., Ehx, G., SOMJA, J., Vrancken, L., Belle, L., SEIDEL, L., Grégoire, C., Fransolet, G., Ritacco, C., Hannon, M., DUBOIS, S., Beguin, Y., Baron, F., & Servais, S. (2019). In Vitro Th17-Polarized Human CD4(+) T Cells Exacerbate Xenogeneic Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 25, 204-215. doi:10.1016/j.bbmt.2018.10.007
Peer Reviewed verified by ORBi

Ehx, G., SOMJA, J., Warnatz, H.-J., Ritacco, C., HANNON, M., Delens, L., Fransolet, G., DELVENNE, P., Muller, J., BEGUIN, Y., Lehrach, H., Belle, L., Humblet-Baron, S., & BARON, F. (2018). Xenogeneic graft-versus-host disease in humanized NSG and NSG-HLA-A2/HHD mice. Frontiers in Immunology, 9, 1943. doi:10.3389/fimmu.2018.01943
Peer Reviewed verified by ORBi

Fransolet, G. (2017). Approche différentielle de la prévention et du traitement de la maladie du greffon contre l’hôte expérimentale de type chronique sclérodermique : focus sur l’Imatinib et l’Azacytidine [Doctoral thesis, Université de Liège]. ORBi-University of Liège. https://orbi.uliege.be/handle/2268/315111

Delens, L., SERVAIS, S., Ehx, G., Vrancken, L., Fransolet, G., GREGOIRE, C., Hannon, M., DUBOIS, S., Daulne, C., BEGUIN, F., & BARON, F. (24 May 2017). Th17 cells impact on xenogeneic graft-versus-host disease [Poster presentation]. 2017 Immunology day FNRS-Immunology Doctoral School, Gosselies, Belgium.

Delens, L., SERVAIS, S., Vrancken, L., Ehx, G., Fransolet, G., Hannon, M., DUBOIS, S., Daulne, C., Beguin, Y., & Baron, F. (27 March 2017). Xenogeneic graft-versus-host disease : Impact of Th17 cells [Poster presentation]. 43rd Annual Meeting of the European Society for Blood and Marrow Transplantation, Marseille, France.

Ehx, G., SOMJA, J., Fransolet, G., Delens, L., Muller, J., BEGUIN, Y., Humblet-Baron, S., Hannon, M., & BARON, F. (10 February 2017). Comparison of xenogeneic graft-versus-host reactions in humanized NSG and NSG-HLA-A2/HHD mice [Poster presentation]. 32nd General Annual Meeting of the Belgian Hematological Society, Bruxelles, Belgium.

Ehx, G., SOMJA, J., Delens, L., Fransolet, G., DELVENNE, P., Muller, J., BEGUIN, Y., Hannon, M., Humblet-Baron, S., & BARON, F. (01 February 2017). Comparison of xenogeneic graft-versus-host reactions in humanized NSG and NSG-HLA-A2/HHD mice [Paper presentation]. GIGA-Day 2017: New insights into the hallmark of cancer, Liège, Belgium.

Delens, L., SERVAIS, S., Vrancken, L., Ehx, G., Fransolet, G., Hannon, M., DUBOIS, S., Daulne, C., BEGUIN, Y., & BARON, F. (February 2017). Impact of Th17 population on xenogeneic graft-versus-host disease [Poster presentation]. 32nd General Annual Meeting of the Belgian Hematology Society, La Hulpe, Belgium.

Ehx, G., Fransolet, G., De Leval, L., D'Hondt, S., Lucas, S., Hannon, M., Delens, L., DUBOIS, S., Drion, P., Beguin, Y., Humblet-Baron, S., & Baron, F. (2017). Azacytidine prevents experimental xenogeneic graft-versus-host disease without abrogating graft-versus-leukemia effects. Oncoimmunology, 6:e1314425. doi:10.1080/2162402X.2017.1314425
Peer Reviewed verified by ORBi

Belle, L.* , Fransolet, G.* , Somja, J., BINSFELD, M., Delvenne, P., Drion, P., Hannon, M., BEGUIN, Y., Ehx, G.* , & Baron, F.*. (12 December 2016). Limited Impact of Imatinib in a Murine Model of Sclerodermatous Chronic Graft-versus-Host Disease. PLoS ONE, 11, 0167997. doi:10.1371/journal.pone.0167997
Peer Reviewed verified by ORBi
* These authors have contributed equally to this work.

Delens, L., SERVAIS, S., Vrancken, L., Ehx, G., Fransolet, G., Hannon, M., DUBOIS, S., Daulne, C., BEGUIN, Y., & Baron, F. (08 December 2016). Xenogeneic graft-versus-host disease: Impact of Th17 cells [Poster presentation]. Journée des chercheurs Télévie 2017, Bruxelles, Belgium.

Fransolet, G., Belle, L., SOMJA, J., DELVENNE, P., Hannon, M., Drion, P., BINSFELD, M., BEGUIN, Y., Ehx, G., & Baron, F. (08 December 2016). Limited impact of imatinib in a murine model of sclerodermatous chronic graft-versus-host disease (scl-cGVHD) [Paper presentation]. Séminaire des chercheurs Télévie 2017, Bruxelles, Belgium.

Ehx, G., Fransolet, G., de Leval, L., D'Hondt, S., Lucas, S., Hannon, M., Delens, L., DUBOIS, S., Drion, P., BEGUIN, Y., Humblet-Baron, S., & BARON, F. (18 November 2016). Azacytidine prevents experimental xenogeneic graft-versus-host disease without abrogating graft-versus-leukemia effects [Paper presentation]. Congrès Commun de la SFGM-TC et de la SFBCT, Liège, Belgium.

Delens, L., SERVAIS, S., Ehx, G., Vrancken, L., Fransolet, G., GREGOIRE, C., Hannon, M., DUBOIS, S., Daulne, C., BEGUIN, Y., & BARON, F. (18 November 2016). Impact des cellules Th17 sur la GVH xénogénique [Paper presentation]. 16ème édition du congrès de la SFGM-TC, Société Francophone de Greffe de Moelle et de Thérapie Cellulaire, Liège, Belgium.

Belle, L., Fransolet, G., SOMJA, J., BINSFELD, M., DELVENNE, P., Drion, P., Hannon, M., BEGUIN, Y., Ehx, G., & Baron, F. (17 November 2016). Limited impact of imatinib in a murine model of sclerodermic chronic graft-versus-host disease [Poster presentation]. 16ème congrès de la Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC) en commun avec la SFBCT, Liège, Belgium.

Ehx, G., Somja, J., Fransolet, G., Delens, L., Muller, J., Beguin, Y., Humblet-Baron, S., & Baron, F. (14 October 2016). Comparison of xenogeneic graft-versus-host reactions in humanized NSG and NSG-HLA-A2/HHD mice [Poster presentation]. Regulatory T cells mini-symposium, Leuven, Belgium.

Ehx, G., Fransolet, G., de Leval, L., D'Hondt, S., Lucas, S., Hannon, M., Delens, L., Drion, P., BEGUIN, Y., Humblet-Baron, S., & BARON, F. (14 October 2016). Azacytidine prevents experimental xenogeneic graft-versus-host disease without abrogating graft-versus-leukemia effects [Poster presentation]. Regulatory T cell mini-symposium, Leuven, Belgium.

Fransolet, G.* , Ehx, G.* , SOMJA, J., Delens, L., Hannon, M., Muller, J., DUBOIS, S., Drion, P., CAERS, J., Humblet-Baron, S., DELVENNE, P., BEGUIN, Y., Conteduca, G.* , & BARON, F.*. (04 July 2016). Azacytidine mitigates experimental sclerodermic chronic graft-versus-host disease. Journal of Hematology and Oncology, 9, 53. doi:10.1186/s13045-016-0281-2
Peer Reviewed verified by ORBi
* These authors have contributed equally to this work.

Delens, L., BEGUIN, Y., Vrancken, L., Ehx, G., Fransolet, G., Hannon, M., DUBOIS, S., Daulne, C., SERVAIS, S., & BARON, F. (27 May 2016). Th17 cell population seems to aggravate xenogeneic graft-versus-host disease [Poster presentation]. 2016 Immunology day FNRS-Immunology Doctoral School, Gosselies, Belgium.

SERVAIS, S., BEGUIN, Y., Delens, L., Ehx, G., Fransolet, G., Hannon, M., WILLEMS, E., Humblet-Baron, S., Belle, L., & Baron, F. (11 May 2016). Novel approaches for preventing acute graftversus- host disease after allogeneic hematopoietic stem cell transplantation. Expert Opinion on Investigational Drugs, 9, 957-972. doi:10.1080/13543784.2016.1182498
Peer Reviewed verified by ORBi

Ehx, G., Fransolet, G., de Leval, L., D'Hondt, S., Lucas, S., Hannon, M., Delens, L., DUBOIS, S., Drion, P., Beguin, Y., Humblet-Baron, S., & Baron, F. (March 2016). Azacytidine Enhances Regulatory T-Cells In Vivo and Prevents Experimental Xenogeneic Graft-Versus-Host Disease. Biology of Blood and Marrow Transplantation, 22 (3), 393. doi:10.1016/j.bbmt.2015.11.917
Peer Reviewed verified by ORBi

Delens, L., SERVAIS, S., Vrancken, L., Ehx, G., Fransolet, G., Hannon, M., DUBOIS, S., Daulne, C., BEGUIN, Y., & Baron, F. (29 January 2016). Salt but not glucocorticoïds enhances Th17 differentiation from naïve T cells in vitro [Poster presentation]. 31st General Annual Meeting of the Belgian Hematological Society, La Hulpe, Belgium.

Fransolet, G., Ehx, G., SOMJA, J., Delens, L., Hannon, M., DUBOIS, S., Drion, P., CAERS, J., Humblet-Baron, S., Belle, L., DELVENNE, P., BEGUIN, Y., Conteduca, G., & Baron, F. (29 January 2016). Azacytidine and Decitabine prevent experimental sclerodermic chronic graft-versus-host disease [Poster presentation]. 31st general annual meeting of the Belgian Hematological Society, La Hulpe, Belgium.

Delens, L., Servais, S., Hannon, M., Ehx, G., Fransolet, G., DUBOIS, S., Daulne, C., Vrancken, L., Beguin, Y., & Baron, F. (03 December 2015). Revisiting Th17 cell subsets in the setting of allogeneic stem cell transplantation and (cortico-refractory) graft-versus-host disease [Poster presentation]. Journée Télévie 2016, Gembloux, Belgium.

Fransolet, G., Ehx, G., SOMJA, J., Hannon, M., DUBOIS, S., Drion, P., CAERS, J., Humblet-Baron, S., Belle, L., Delvenne, P., BEGUIN, Y., Conteduca, G., & Baron, F. (19 November 2015). L'Azacytidine comme traitement de la maladie du greffon contre l'hôte de type chronique sclérodermique expérimentale [Paper presentation]. 15ème congrès de la Société Française de Greffe de Moelle et de Thérapie Cellulaire, Clermont-Ferrand, France.

Ehx, G., Fransolet, G., de Leval, L., D'Hondt, S., Lucas, S., Hannon, M., Delens, L., DUBOIS, S., Drion, P., BEGUIN, Y., Humblet-Baron, S., & BARON, F. (13 November 2015). Azacytidine prevents experimental xenogeneic graft-versus-host disease without abrogating graft-versus-leukemia effects [Paper presentation]. EORTC Leukemia Group-GIMEMA meeting, Rome, Italy.

Fransolet, G., Ehx, G., SOMJA, J., Belle, L., Drion, P., Humblet-Baron, S., Beguin, Y., & Baron, F. (30 January 2015). Azacytidine prevents experimental sclerodermic chronic graft-versus-host disease [Poster presentation]. 30th general annual meeting of the Belgian Hematological Society, La Hulpe, Belgium.

Delens, L., SERVAIS, S., Hannon, M., Ehx, G., Fransolet, G., DUBOIS, S., Beguin, Y., & Baron, F. (30 January 2015). Effects of Tocilizumab on Th17 cell differentiation in a humanized mouse model of xenogeneic graft-versus-host disease [Poster presentation]. 30st General Annual Meeting of the Belgian Hematological Society, La Hulpe, Belgium.

Fransolet, G., Belle, L., SOMJA, J., Humblet-Baron, S., DUBOIS, S., Delvenne, P., Beguin, Y., & Baron, F. (January 2014). Imatinib improves survival of chronic Graft-versus-host disease by inhibiting TGF-β and PDGF-R in mice [Poster presentation]. 29th general annual meeting of the Belgian Hematological Society, Ghent, Belgium.

Belle, L., Ehx, G., SOMJA, J., Binsfeld, M., HANNON, M., CAERS, J., Fransolet, G., BEGUIN, Y., Humblet-Baron, S., & Baron, F. (December 2013). Combination Of Regulatory T Cells and Rapamycin As Treatment For Experimental Chronic Graft-Versus-Host Disease [Poster presentation]. 55th Annual Meeting of the American Society of Hematology.

Belle, L., Ehx, G., SOMJA, J., BINSFELD, M., Hannon, M., Caers, J., Fransolet, G., Beguin, Y., Humblet-Baron, S., & Baron, F. (December 2013). Combination Of Regulatory T Cells and Rapamycin As Treatment For Experimental Chronic Graft-Versus-Host Disease. Blood, 122 (21), 4474.
Peer Reviewed verified by ORBi

Contact ORBi